Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific ...

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer ...

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp. (MSFT), AstraZeneca ...

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca is pioneering new ways ...

Download to gain expert insights and data-driven analysis from the ASCO 2025 Annual Meeting. This report covers key ...

It sounds too simple to be true. Exercise works just as effectively as a drug to slash the risk of dying from bowel cancer, ...

A recent trial reveals that durvalumab enhances event-free survival in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

The SMC has also has accepted Cladribine, also known as Mavenclad, for the treatment of relapsing-remitting multiple ...

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is undergoing a significant transformation in its therapeutic and competitive landscape. Accounting for approximately 75% ...